Sector
PharmaceuticalsOpen
₹277Prev. Close
₹276.86Turnover(Lac.)
₹894.47Day's High
₹277.23Day's Low
₹244.5652 Week's High
₹323.5352 Week's Low
₹131.2Book Value
₹9.84Face Value
₹10Mkt Cap (₹ Cr.)
838.53P/E
49.32EPS
5.6Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 38.75 | 32.71 | 32.67 | 25.02 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -10.8 | -39.96 | -30.48 | -155.67 |
Net Worth | 27.95 | -7.25 | 2.19 | -130.65 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 392.51 | 367.45 | 371.66 | 433.8 |
yoy growth (%) | 6.82 | -1.13 | -14.32 | 2.49 |
Raw materials | -217.14 | -175.73 | -174.09 | -196.97 |
As % of sales | 55.32 | 47.82 | 46.84 | 45.4 |
Employee costs | -64.14 | -67.47 | -87.32 | -87.77 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -12.4 | -17.96 | -32.36 | 62.4 |
Depreciation | -9.75 | -9.68 | -10.3 | -10.31 |
Tax paid | -0.2 | -0.2 | 0.37 | -0.38 |
Working capital | -11.56 | -7.53 | -58.84 | -73.01 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.82 | -1.13 | -14.32 | 2.49 |
Op profit growth | -23.14 | -134.75 | -464.11 | -42.95 |
EBIT growth | -28.4 | -1,016.65 | -101.66 | 294.25 |
Net profit growth | -119.55 | -301.52 | -151.57 | -981.55 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 575.65 | 499.65 | 511.19 | 392.52 | 367.45 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 575.65 | 499.65 | 511.19 | 392.52 | 367.45 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 28.55 | 0.91 | 77.88 | 2.4 | 83.78 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,787.4 | 137.43 | 4,32,960 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,012.5 | 79.59 | 1,65,003.32 | 594 | 0.48 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,525.9 | 26.92 | 1,25,285.64 | 1,438.15 | 0.84 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,238.9 | 61.67 | 1,12,502.67 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,557.5 | 55.53 | 1,07,385.94 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Vice Chairman & Whole Time Dir
K Chandran
Company Sec. & Compli. Officer
Jitendra J Gandhi
Independent Director
Pravin Dilip Pawar
Independent Director
Anupam Vaidya
Whole Time Director
Mohan Kumar Rayana
Independent Director
Mridul Sumanlal Mehta
Additional Director
Pallavur Sankar Dass Vaidyanathan
Additional Director
Manojkumar Khubchand Gursahani
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Wanbury Ltd
Summary
Wanbury Ltd (Formerly known Pearl Organics Limited) was incorporated in August, 1988. The Company is engaged in the business of pharmaceutical and related activities, including research.The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs. In 1995, the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga. In 1996, it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US.In 2007-08, the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April, 2007. Pursuant to the aforesaid Order of the Honble Bl FR 7,85,557 Equity Shares of face value of Rs. 10/- each of the Company were issued to the Equity Shareholders of DOCL on 17th March, 2008. Similarly, the Pharmaceutical Products of India Limited (PPIL) was merged with the Company effective from April 1, 2006. In terms of the said Scheme of Merger, the Company had issued 5,62,618 Equity Shares of face value of Rs. 10/- each to the Equity Shareholders of PPIL on 27 June, 2007, which got listed on Bombay Stock Exchange Limited and National Stock Exchange Limited respectively.The company entered into a strategic association with Bravo Healthcare Ltd and incorporated Ningxia Wanbury Fine Chemicals Co Ltd to source raw materials from China. It opened its office in Zurich,Switzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008.Th
Read More
The Wanbury Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹255.88 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Wanbury Ltd is ₹838.53 Cr. as of 25 Apr ‘25
The PE and PB ratios of Wanbury Ltd is 49.32 and 23.35 as of 25 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Wanbury Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Wanbury Ltd is ₹131.2 and ₹323.53 as of 25 Apr ‘25
Wanbury Ltd's CAGR for 5 Years at 65.87%, 3 Years at 50.51%, 1 Year at 71.22%, 6 Month at 24.21%, 3 Month at 18.44% and 1 Month at 4.34%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.